These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review. Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887 [TBL] [Abstract][Full Text] [Related]
44. Loss of circadian gene Timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism. Colangelo T; Carbone A; Mazzarelli F; Cuttano R; Dama E; Nittoli T; Albanesi J; Barisciano G; Forte N; Palumbo O; Graziano P; di Masi A; Colantuoni V; Sabatino L; Bianchi F; Mazzoccoli G Cell Death Differ; 2022 Aug; 29(8):1552-1568. PubMed ID: 35034102 [TBL] [Abstract][Full Text] [Related]
45. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779 [TBL] [Abstract][Full Text] [Related]
46. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137 [TBL] [Abstract][Full Text] [Related]
53. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026 [TBL] [Abstract][Full Text] [Related]
54. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Krebs AM; Mitschke J; Lasierra Losada M; Schmalhofer O; Boerries M; Busch H; Boettcher M; Mougiakakos D; Reichardt W; Bronsert P; Brunton VG; Pilarsky C; Winkler TH; Brabletz S; Stemmler MP; Brabletz T Nat Cell Biol; 2017 May; 19(5):518-529. PubMed ID: 28414315 [TBL] [Abstract][Full Text] [Related]
55. Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. Liu Z; Sun B; Qi L; Li H; Gao J; Leng X Cancer Sci; 2012 Apr; 103(4):813-20. PubMed ID: 22212097 [TBL] [Abstract][Full Text] [Related]
56. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression. Weng WH; Leung WH; Pang YJ; Hsu HH Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897 [TBL] [Abstract][Full Text] [Related]
57. Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers. Mahmoud A; Elkhalifa D; Alali F; Al Moustafa AE; Khalil A Curr Pharm Des; 2020; 26(14):1622-1633. PubMed ID: 32026770 [TBL] [Abstract][Full Text] [Related]
58. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750 [TBL] [Abstract][Full Text] [Related]
59. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571 [TBL] [Abstract][Full Text] [Related]
60. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer. He Z; Thorrez L; Siegfried G; Meulemans S; Evrard S; Tejpar S; Khatib AM; Creemers JWM Oncogene; 2020 Apr; 39(17):3571-3587. PubMed ID: 32139876 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]